MedPath

RZL-012

Generic Name
RZL-012
Clinical Trials
Related News

An Open-label Study That Will Test a Second Treatment Session of RZL-012.

Phase 2
Completed
Conditions
Submental Fat
Interventions
First Posted Date
2023-03-10
Last Posted Date
2023-11-18
Lead Sponsor
Raziel Therapeutics Ltd.
Target Recruit Count
15
Registration Number
NCT05763160
Locations
🇺🇸

Luxurgery, Manhattan, New York, United States

Evaluation the Effects of Various Treatments on RZL-012-Induced Adverse Events

Phase 1
Completed
Conditions
Submental Fat
Interventions
Drug: RZL-012+Lidacaine injection prior treatment
Drug: RZL-012+Medrol
Drug: RZL-012+Celecoxib+Zyrtec
Drug: RZL-012+facial and neck wrap
First Posted Date
2022-07-27
Last Posted Date
2024-01-30
Lead Sponsor
Raziel Therapeutics Ltd.
Target Recruit Count
48
Registration Number
NCT05476679
Locations
🇺🇸

Luxurgery, Manhattan, New York, United States

An Open Label Study That Will Test Safety and Efficacy of RZL-012 Injection Into the Submental Fat in Chinese vs. Non-Chinese Subjects.

Phase 1
Completed
Conditions
Submental Fat
Interventions
First Posted Date
2022-07-20
Last Posted Date
2023-12-19
Lead Sponsor
Raziel Therapeutics Ltd.
Target Recruit Count
20
Registration Number
NCT05466448
Locations
🇺🇸

Luxurgery, New York, New York, United States

Evaluation of Safety and Efficacy of RZL-012 in Subjects Seeking Fat Reduction in the Flanks

Phase 2
Completed
Conditions
Flank Mass
Interventions
Drug: Placebo
First Posted Date
2022-07-06
Last Posted Date
2023-11-18
Lead Sponsor
Raziel Therapeutics Ltd.
Target Recruit Count
12
Registration Number
NCT05445557
Locations
🇺🇸

Luxurgery, New York, New York, United States

Efficacy and Safety of RZL-012 on Submental Fat Reduction

Phase 2
Completed
Conditions
Submental Fat
Interventions
Drug: Placebo
First Posted Date
2021-04-30
Last Posted Date
2023-09-28
Lead Sponsor
Raziel Therapeutics Ltd.
Target Recruit Count
151
Registration Number
NCT04867434
Locations
🇺🇸

DenovaResearch, Chicago, Illinois, United States

RZL-012 for Dercum's Disease Lipomas

Phase 2
Completed
Conditions
Dercum's Disease Lipomas
Interventions
Drug: Vehicle
First Posted Date
2020-01-14
Last Posted Date
2024-02-07
Lead Sponsor
Raziel Therapeutics Ltd.
Target Recruit Count
38
Registration Number
NCT04229030
Locations
🇺🇸

Limitless Therapeutics, Los Angeles, California, United States

A Single Blind, Randomized, Placebo-controlled, Phase 2a, 2-cohort Study for the Evaluation of Safety and Efficacy of RZL-012 for Submental Fat Reduction in Healthy Volunteers.

Phase 2
Completed
Conditions
Submental Fat
Interventions
Drug: Placebo
First Posted Date
2019-09-12
Last Posted Date
2023-11-18
Lead Sponsor
Raziel Therapeutics Ltd.
Target Recruit Count
28
Registration Number
NCT04086823
Locations
🇺🇸

DeNova Research, Chicago, Illinois, United States

Treatment of Women With Lipedema Involving Substantial Fat Knee of Women and Men With Nodular Dercum's Disease

Phase 2
Completed
Conditions
Dercum Disease
Lipedema
Interventions
First Posted Date
2018-04-10
Last Posted Date
2024-02-08
Lead Sponsor
Raziel Therapeutics Ltd.
Target Recruit Count
12
Registration Number
NCT03492840
Locations
🇺🇸

University of Arizona Medical Center, Tucson, Arizona, United States

Evaluation of Safety, Efficacy and Thermogenesis-induction of RZL-012 in Overweight and Obese Volunteers

Phase 2
Completed
Conditions
Obesity
Weight Loss
Overweight and Obesity
Interventions
Drug: Placebo
First Posted Date
2017-05-31
Last Posted Date
2019-08-21
Lead Sponsor
Raziel Therapeutics Ltd.
Target Recruit Count
32
Registration Number
NCT03171415
Locations
🇺🇸

Spaulding Clinical, West Bend, Wisconsin, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy